ESMO Conference Coverage
Featured News
(Forbes) Oct 3, 2019 - New trial suggests that doctor's shouldn't wait to add targeted therapy drugs to standard breast cancer treatment. Results from a clinical trial show that adding ribociclib, a targeted therapy drug, to the standard treatment plan for women with advanced hormone-receptor positive/HER2- breast cancer helps...
(Northwestern Medicine) Sept 30, 2019 - Genetic-based treatment nearly doubles time without disease progression in metastatic prostate cancer. For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially...
(Precision Oncology News) Sept 30, 2019 - Two genomics-centered trials in the Netherlands — the Center for Personalized Cancer Treatment (CPCT-02) and Drug Rediscovery Protocol (DRUP) — are demonstrating the potential for finding tumor genomic features that may guide treatment for advanced cancer patients, even as experts continue...
(Reuters) Sept 28, 2019 - GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class. The two said separately on Saturday their drug candidates - in a class known as...
(BioPharma Dive) Sept 29, 2019 - Women with a type of advanced breast cancer unsuited to drugs like Roche's Herceptin lived significantly longer when given targeted therapies made by Novartis and Eli Lilly, new study results showed. The data, unveiled Sunday at the European Society of Medical Oncology's annual meeting in Barcelona,...
(Bloomberg) Sept 28, 2019 - Bristol-Myers Squibb Co.’s blockbuster oncology drug showed tepid results in a trial of lung-cancer patients, in what investors may read as a setback in the competitive market for drugs that unleash the immune system to attack tumors. The trial compared chemotherapy treatment against a cocktail of...
(Reuters) Sept 28, 2019 - An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in just one of 12 patients with advanced colorectal cancer who were given the highest dose in a small, early-stage trial, the company said on Saturday. The cancer stopped growing in 10 of the patients taking 960 milligrams...
(Reuters) Sept 30, 2019 - AstraZeneca presented results on Monday for a trial of its Lynparza drug against prostate cancer, which it hopes could lead to wider regulatory approval for the treatment for use against more forms of the disease. The British drugmaker, together with development partner Merck & Co, said Lynparza was shown...
(Roche) Sept 27, 2019 - Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone. Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European...
(Roche) Sept 27, 2019 - The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy. The combination of Tecentriq and Avastin was shown to reduce the risk of disease worsening or death by...
(ESMO 2019) Sept 27, 2019 - New data have shown a trend towards clinically meaningful improvements in survival and response rates and a favourable safety profile with first-line immunotherapy compared to current standard treatment for advanced hepatocellular carcinoma (HCC). The data, reported at the ESMO Congress 2019, despite not...
(Reuters) Sept 26, 2019 - GlaxoSmithKline and AstraZeneca will each present trial data on a promising new class of drugs against ovarian cancer on Saturday as Britain’s top drugmakers compete to burnish their oncology credentials. They will unveil results of studies for rival drugs to block a cancer’s ability to repair its genetic...
(Medscape Medical News) Sept 23, 2019 - Final overall survival in breast cancer, immunotherapy in ever-earlier settings, and novel strategies for rare tumor subgroups will be some of the data revealed at Europe's largest oncology meeting. Potentially practice-changing results in breast, lung and ovarian cancer are expected at this...
(Roche) Sept 23, 2019 - First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer. First results from the BFAST study testing Foundation Medicine’s FoundationOne® Liquid biopsy assay to identify patients who may be eligible for Alecensa®...
(Lilly) Sept 23, 2019 - Verzenio® (abemaciclib) Phase 3 data included in ESMO Presidential Symposium and Official Press Program: Positive overall survival results to be presented from MONARCH 2, evaluating Verzenio with fulvestrant for the treatment of women with HR+, HER2- advanced breast cancer whose cancer grew or spread following...
(Bayer) Sept 20, 2019 - New durability of response data for Vitrakvi® (larotrectinib) to be presented in a poster discussion on September 28. Data from Bayer's prostate cancer franchise to be presented, including clinical relevance of drug-drug interactions in men with nmCRPC taking Nubeqa® (darolutamide) and real-world data and...
(BMS) Sept 19, 2019 - Overall survival data from CheckMate -227 Part 1 evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) in advanced non-small cell lung cancer featured in ESMO Presidential Symposium. Five-year survival data on Opdivo plus Yervoy in advanced melanoma from CheckMate -067, the longest follow-up from a dual...
(AstraZeneca) Sept 16, 2019 - Pivotal Phase III data focuses on improving overall survival across lung cancers and breaking treatment boundaries in ovarian, prostate and pancreatic cancers. AstraZeneca will unveil a series of breakthrough data across multiple cancer types in its mission to one day eliminate cancer as a cause of death...
(Vantage) Sept 10, 2019 - Away from the main small-molecule focus of this year’s ESMO meeting, Keytruda flies the flag for immuno-oncology, including in a little-noticed mesothelioma study. Full readout of data from two recently toplined studies looks set to be the highlight for immunotherapies at this month’s Esmo meeting....
View all
More News
(Yahoo! Finance) Oct 9, 2019 - Verzenio plus fulvestrant significantly extended life to a median of 46.7 months vs. 37.3 months compared to fulvestrant alone. MONARCH 2 showed statistically significant results for women whose disease progressed following endocrine therapy. Overall survival results were consistent across subgroups,...
(Yahoo! Finance) Oct 8, 2019 - Adlai Nortye Ltd. announced today at the European Society for Medical Oncology (ESMO) 2019 Congress the first results from a phase 1b neoadjuvant study of AN0025 (previously known as E7046), an investigational, potentially first in class oral EP4 antagonist.
(Vantage) Oct 2, 2019 - An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
(Northwestern Medicine) Sept 30, 2019 - Genetic-based treatment nearly doubles time without disease progression in metastatic prostate cancer. For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially...
(CNN) Sept 30, 2019 - An experimental prostate cancer therapy may change the way patients are treated for the second-deadliest cancer in men. In a "landmark" phase III clinical trial, presented at the European Society of Medical Oncology conference in Barcelona on Monday, the drug olaparib was shown to be safe and effective in...
(Precision Oncology News) Sept 29, 2019 - In presentations at the annual meeting of the European Society for Medical Oncology in Barcelona on Friday, researchers reported seemingly contradictory results on the utility of tumor mutational burden (TMB) as a biomarker for treatment of advanced non-small cell lung cancer (NSCLC) with...
(Precision Oncology News) Sept 30, 2019 - Two genomics-centered trials in the Netherlands — the Center for Personalized Cancer Treatment (CPCT-02) and Drug Rediscovery Protocol (DRUP) — are demonstrating the potential for finding tumor genomic features that may guide treatment for advanced cancer patients, even as experts continue...
(Elevar Therapeutics) Sept 29, 2019 - Elevar Therapeutics announced data from the ANGEL trial, a randomized phase 3 study of rivoceranib (also known as apatinib) plus best supportive care in patients with gastric or gastroesophageal junction cancer who have failed at least 2 prior lines of therapy.
(Immunomedics) Sept 28, 2019 - Immunomedics today presented at the European Society for Medical Oncology (ESMO) Annual Congress interim data from the 100-patient cohort of cisplatin-eligible patients of the Company’s TROPHY-U-01 open-label Phase 2 study.
(Yahoo! Finance) Sept 30, 2019 - Tyme Technologies, Inc. announced that its open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging overall (OS) results and has a well-tolerated safety profile.
(G1 Therapeutics) Sept 28, 2019 - G1 Therapeutics, Inc. today reported preliminary overall survival (OS) data from the company’s randomized Phase 2 trial of trilaciclib in combination with chemotherapy for the treatment of metastatic triple-negative breast cancer (mTNBC).
(G1 Therapeutics) Sept 29, 2019 - G1 Therapeutics, Inc. today announced preliminary results from a Phase 1/2a dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer.
(Aileron) Sept 28, 2019 - Aileron Therapeutics announced the presentation of interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer’s IBRANCE® (palbociclib) for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification at ESMO...
(Yahoo! Finance) Oct 1, 2019 - Study results demonstrate that oral SM-88 may play a clinically meaningful role in postponing use of hormonal castration in prostate cancer patients with rising prostate-specific antigen (PSA): More than 450,000 of these patient cases annually in the U.S. alone.
Featured Videos
There are no featured ESMO 2019 videos.

OBR Tweets

Jul 09
H. Jack West, MD: The benefit of low dose chest CT screening for lung cancer remains somewhat controversial, but th… https://t.co/8wOgsSCY7q

Jul 08
Howard S. Hochster, MD: While a "complete response" is great for our patients, the Complete Response Letter was les… https://t.co/yQGkfvpMCF

Jul 02
A panel of three breast cancer experts looked at some of the big studies at #ASCO20 and discussed treatment advance… https://t.co/ve0XD0cWDY

Jul 01
A report on several promising studies at #ASCO20 focused on personalized therapies for patients with unmet needs. I… https://t.co/lc4BoQ3Evl

Jul 01
At #ASCO’s virtual meeting, studies featured potentially practice-changing data. Among the studies were the BOSTON… https://t.co/6pXpxFomwu

Jun 22
Howard S. Hochster, MD: Another, but far more problematic approval for Pembro. Which tumors actually have high TMB… https://t.co/pBSquns9mN

Jun 19
Dean Gesme, MD: The positive primary endpoint of improved iDFS with Abemaciclib plus adjuvant AI in this Monarch E… https://t.co/GXnYhO8jov

Jun 17
Thomas Marsland, MD: I actually enjoyed the experience. I certainly missed mingling with friends and colleagues. Al… https://t.co/gVtYjkzPzy

Jun 16
Derek Raghavan, MD, on @LevineCancer provides a general overview of prostate cancer therapies #ASCO20 https://t.co/niwz0yPHjB

Jun 16
H. Jack West, MD: We await phase 3 data, but many will welcome a new option with an approximately 35% response rate… https://t.co/Ld5N8KrWye